Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
06/10/2023 | 22:07 | Edgar (US Regulatory) | Form 15-12G - Securities registration termination [Section 12(g)] | NASDAQ:RETA | Reata Pharmaceuticals Inc |
28/09/2023 | 22:30 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | NASDAQ:RETA | Reata Pharmaceuticals Inc |
27/09/2023 | 01:18 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:RETA | Reata Pharmaceuticals Inc |
26/09/2023 | 23:25 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:RETA | Reata Pharmaceuticals Inc |
26/09/2023 | 22:25 | Edgar (US Regulatory) | Form POSASR - Post-effective Amendment to an automatic shelf registration statement | NASDAQ:RETA | Reata Pharmaceuticals Inc |
26/09/2023 | 22:23 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:RETA | Reata Pharmaceuticals Inc |
26/09/2023 | 14:59 | GlobeNewswire Inc. | Biogen Completes Acquisition of Reata Pharmaceuticals | NASDAQ:RETA | Reata Pharmaceuticals Inc |
21/09/2023 | 16:08 | Business Wire | Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc. | NASDAQ:RETA | Reata Pharmaceuticals Inc |
14/09/2023 | 22:26 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:RETA | Reata Pharmaceuticals Inc |
12/09/2023 | 19:20 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:RETA | Reata Pharmaceuticals Inc |
22/08/2023 | 14:00 | Edgar (US Regulatory) | Form DEFM14A - Definitive proxy statement relating to merger or acquisition | NASDAQ:RETA | Reata Pharmaceuticals Inc |
11/08/2023 | 22:38 | Edgar (US Regulatory) | Form PREM14A - Preliminary proxy statements relating to merger or acquisition | NASDAQ:RETA | Reata Pharmaceuticals Inc |
31/07/2023 | 13:20 | IH Market News | Monday’s Wall Street Highlights: Palantir Technologies, Walmart, Yellow Corp, J&J, and more | NASDAQ:RETA | Reata Pharmaceuticals Inc |
28/07/2023 | 13:05 | GlobeNewswire Inc. | Biogen to Acquire Reata Pharmaceuticals | NASDAQ:RETA | Reata Pharmaceuticals Inc |
28/06/2023 | 13:20 | Dow Jones News | Reata Pharma Shares Climb Premarket After FDA OKs Prior-Approval Supplement for Skyclarys | NASDAQ:RETA | Reata Pharmaceuticals Inc |
28/06/2023 | 01:29 | Business Wire | Reata Pharmaceuticals Announces Approval of Prior Approval Supplement for SKYCLARYS® (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich’s Ataxia | NASDAQ:RETA | Reata Pharmaceuticals Inc |
26/06/2023 | 22:47 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:RETA | Reata Pharmaceuticals Inc |
16/06/2023 | 22:04 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:RETA | Reata Pharmaceuticals Inc |
16/06/2023 | 01:15 | Business Wire | Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS® (Omaveloxlone) NDA Prior Approval Supplement | NASDAQ:RETA | Reata Pharmaceuticals Inc |
14/06/2023 | 00:27 | Edgar (US Regulatory) | Report of Proposed Sale of Securities (144) | NASDAQ:RETA | Reata Pharmaceuticals Inc |
13/06/2023 | 12:45 | Business Wire | Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer | NASDAQ:RETA | Reata Pharmaceuticals Inc |
09/06/2023 | 11:45 | PR Newswire (US) | RETA FRAUD ALERT: Jakubowitz Law is Investigating Reata Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws | NASDAQ:RETA | Reata Pharmaceuticals Inc |
07/06/2023 | 22:02 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:RETA | Reata Pharmaceuticals Inc |
07/06/2023 | 11:45 | PR Newswire (US) | INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Reata Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit - (NASDAQ: RETA) | NASDAQ:RETA | Reata Pharmaceuticals Inc |
06/06/2023 | 22:31 | Business Wire | Reata Pharmaceuticals Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference | NASDAQ:RETA | Reata Pharmaceuticals Inc |
15/05/2023 | 22:36 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:RETA | Reata Pharmaceuticals Inc |
10/05/2023 | 12:40 | Business Wire | Reata Pharmaceuticals, Inc. Announces First Quarter 2023 Financial Results and Provides an Update on Operational Progress and Clinical Development Programs | NASDAQ:RETA | Reata Pharmaceuticals Inc |
02/05/2023 | 23:45 | Business Wire | Reata Pharmaceuticals, Inc. to Report First Quarter 2023 Financial Results and to Provide an Update on Operational Progress and Clinical Development Programs on May 10, 2023 | NASDAQ:RETA | Reata Pharmaceuticals Inc |
28/04/2023 | 12:23 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) | NASDAQ:RETA | Reata Pharmaceuticals Inc |
28/04/2023 | 12:23 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) | NASDAQ:RETA | Reata Pharmaceuticals Inc |